| Drug Name |
Mercaptopurine |
| Drug ID |
BADD_D01392 |
| Description |
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. |
| Indications and Usage |
For remission induction and maintenance therapy of acute lymphatic leukemia. |
| Marketing Status |
approved |
| ATC Code |
L01BB02 |
| DrugBank ID |
DB01033
|
| KEGG ID |
D00161; D04931
|
| MeSH ID |
D015122
|
| PubChem ID |
667490
|
| TTD Drug ID |
D09UZO
|
| NDC Product Code |
62991-2899; 69076-913; 15308-0712; 12780-0299; 0054-4581; 0378-3547 |
| UNII |
E7WED276I5
|
| Synonyms |
Mercaptopurine | 6H-Purine-6-thione, 1,7-dihydro- | 6-Mercaptopurine Monohydrate | 6 Mercaptopurine Monohydrate | 6-Thiopurine | 6 Thiopurine | 1,7-Dihydro-6H-purine-6-thione | 6-Mercaptopurine | 6 Mercaptopurine | 6-Thiohypoxanthine | 6 Thiohypoxanthine | Purinethol | Puri-Nethol | Mercaptopurina Wellcome | Leupurin | BW 57-323H | BW 57 323H | BW 57323H | Purimethol | Mecaptopurine Anhydrous |
